Trial Profile
PHASE 1 DOSE ESCALATION TRIAL OF β-LAPACHONE (ARQ761) IN COMBINATION WITH PARP INHIBITOR, OLAPARIB, FOR REFRACTORY, ADVANCED SOLID TUMORS
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs ARQ 761 (Primary) ; Olaparib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 23 Sep 2019 Planned End Date changed from 23 Aug 2023 to 15 May 2019.
- 23 Sep 2019 Planned primary completion date changed from 23 Aug 2022 to 15 May 2019.
- 23 Sep 2019 Planned initiation date changed from 30 Jun 2019 to 25 Jun 2018.